pulmonary arterial hypertension

Gossamer Bio and Chiesi Group to collaborate in therapy for lung condition
Reuters
Mon, 05/6/24 - 11:35 am
Gossamer Bio
The Chiesi Group
seralutinib
PAH
pulmonary arterial hypertension
Merck nails phase 3 sotatercept win, making good on its $11.5B Acceleron buy
Fierce Biotech
Mon, 10/10/22 - 11:06 am
Merck
Acceleron
clinical trials
sotatercept
PAH
pulmonary arterial hypertension
Here's What Lifted Arena Pharmaceuticals, Inc. Stock in September
Motley Fool
Tue, 10/10/17 - 09:36 am
Arena Pharmaceuticals
ralinepag
PAH
pulmonary arterial hypertension
Arena Pharma Skyrockets on Heart Disease Data, Stock Could Still Double -Firm Says
TheStreet.com
Mon, 07/17/17 - 07:05 pm
Arena Pharmaceuticals
ralinepag
PAH
pulmonary arterial hypertension
Arena takes a big step down the comeback trail with PhII success, shares rocket up
Endpoints
Tue, 07/11/17 - 11:18 am
Arena Pharmaceuticals
PAH
clinical trials
pulmonary arterial hypertension
ralinepag
How Is United Therapeutics’ Remodulin Positioned in 2017?
Market Realist
Mon, 07/3/17 - 09:46 am
United Therapeutics
Remodulin
PAH
pulmonary arterial hypertension
EMA panel recommends that use of Actelion's Uptravi may continue
Yahoo/Reuters
Sat, 02/11/17 - 12:32 pm
Europe
Actelion
Uptravi
pulmonary arterial hypertension
PAH
France
Actelion drug fails trial, denting revenue potential
Yahoo/Reuters
Mon, 01/23/17 - 10:19 am
Actelion
clinical trials
Opsumit
PAH
pulmonary arterial hypertension
United Therapeutics sees stepped-up competition and says it's 'a good thing'
Bizjournals.com
Tue, 03/1/16 - 10:59 pm
United Therapeutics
PAH
pulmonary arterial hypertension
Could an old Roche arthritis med become a pioneering PAH treatment?
BioPharma Dive
Thu, 01/7/16 - 09:32 am
Roche
PAH
pulmonary arterial hypertension
tocilizumab
Actemra
Actelion sees Uptravi price of $160,000-170,000/patient
Yahoo/Reuters
Tue, 01/5/16 - 02:47 pm
Actelion
Uptravi
PAH
pulmonary arterial hypertension
Actelion says selexipag to enter U.S. market in January
Yahoo/Reuters
Tue, 12/22/15 - 10:56 am
Actelion
selexipag
Uptravi
PAH
pulmonary arterial hypertension
With Opsumit launch rolling, Actelion doesn't 'need' M&A: CEO
Fierce Pharma
Tue, 10/20/15 - 09:53 pm
Actelion
Opsumit
M&A
PAH
pulmonary arterial hypertension
Gilead Sciences Letairis Wins FDA Nod For PAH: Stock To Recover Soon
Bidness, ETC
Tue, 10/6/15 - 09:51 am
PAH
pulmonary arterial hypertension
FDA
Gilead Sciences
Letairis
Bellerophon shares skyrocket on high blood pressure drug study
Marketwatch
Thu, 09/24/15 - 07:19 pm
Bellerophon
PAH
Inopulse
clinical trials
pulmonary arterial hypertension
Actelion's Opsumit growth heralds smooth switch off aging Tracleer
Fierce Pharma
Tue, 07/21/15 - 10:34 am
Actelion
Opsumit
Tracleer
PAH
pulmonary arterial hypertension
Deep dive into Actelion's Uptravi data calms investors as FDA decision date nears
Fierce Biotech
Wed, 03/18/15 - 11:08 am
Actelion
Uptravi
PAH
pulmonary arterial hypertension
GSK and Gilead’s combination therapy: positive results in PAH
Pharmaphorum
Tue, 09/9/14 - 10:36 am
GSK
Gilead Sciences
PAH
pulmonary arterial hypertension
Letairis
Adcirca
Arena Pharmaceuticals' APD811 Gets Orphan Drug Status
Yahoo/Zacks.com
Thu, 09/4/14 - 08:01 am
Arena Pharmaceuticals
APD811
orphan drugs
PAH
pulmonary arterial hypertension
Phase 4 Actelion Study Misses Primary Endpoint
Forbes
Mon, 03/17/14 - 04:58 pm
Actelion
Tracleer
pulmonary arterial hypertension

Pages